Bausch Health Companies and Ortho Dermatologics announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating the investigational medicine IDP-126, a combination retinoid, anti-bacterial and antibiotic topical to treat acne vulgaris in patients 9 years of age and older.

The U.S. Food and Drug Administration approved Italy-based Cassiopea SpA’s acne treatment Winlevi (clascoterone cream 1%).

The U.S. FDA approved Ortho Dermatologics’ NDA for Altreno (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.